McKinley Carter Wealth Services Inc. decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 3.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,709 shares of the medical research company’s stock after selling 99 shares during the period. McKinley Carter Wealth Services Inc.’s holdings in Amgen were worth $467,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the company. Financial Advisory Service Inc. grew its holdings in shares of Amgen by 0.3% during the 2nd quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock valued at $340,000 after purchasing an additional 5 shares during the last quarter. Capital Advisors Ltd. LLC boosted its position in Amgen by 0.6% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock valued at $190,000 after buying an additional 7 shares during the period. Ballentine Partners LLC boosted its position in Amgen by 0.3% during the 2nd quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock valued at $620,000 after buying an additional 9 shares during the period. Hudock Capital Group LLC boosted its position in Amgen by 0.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock valued at $330,000 after buying an additional 10 shares during the period. Finally, Investment Partners Ltd. OH ADV boosted its position in Amgen by 0.5% during the 2nd quarter. Investment Partners Ltd. OH ADV now owns 2,192 shares of the medical research company’s stock valued at $377,000 after buying an additional 11 shares during the period. 78.20% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://transcriptdaily.com/2017/11/14/amgen-inc-amgn-shares-sold-by-mckinley-carter-wealth-services-inc.html.
AMGN has been the subject of several research analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $195.00 target price on shares of Amgen in a research report on Monday, July 17th. BMO Capital Markets cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 target price for the company. in a research report on Friday, July 21st. They noted that the move was a valuation call. Cowen and Company reaffirmed an “outperform” rating and issued a $209.00 target price on shares of Amgen in a research report on Saturday, July 22nd. Cann reaffirmed a “buy” rating and issued a $203.00 target price (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and issued a $174.00 target price (up from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. Thirteen research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. Amgen currently has a consensus rating of “Buy” and an average price target of $190.03.
In other news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.
Shares of Amgen Inc. (NASDAQ AMGN) opened at $171.50 on Tuesday. The stock has a market cap of $125,110.70, a price-to-earnings ratio of 13.70, a PEG ratio of 2.50 and a beta of 1.37. Amgen Inc. has a one year low of $138.83 and a one year high of $191.10. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07.
Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business’s revenue was down .7% on a year-over-year basis. During the same period in the previous year, the firm earned $3.02 earnings per share. sell-side analysts predict that Amgen Inc. will post 12.66 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be paid a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.68%. The ex-dividend date is Thursday, November 16th. Amgen’s dividend payout ratio is currently 41.63%.
Amgen announced that its Board of Directors has initiated a share buyback plan on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.